¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.
¹Ì±¹ÀÇ ÀǾàǰ ºÐ¼® ½ÃÇè ¾Æ¿ô¼Ò½Ì ½ÃÀå ¼ºÀå ¹× µ¿Çâ:
Grand View Research, Inc.ÀÇ ÃֽŠº¸°í¼¿¡ µû¸£¸é, ¹Ì±¹ÀÇ ÀǾàǰ ºÐ¼® ½ÃÇè ¾Æ¿ô¼Ò½Ì ½ÃÀå ±Ô¸ð´Â 2030³â±îÁö 50¾ï 9,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
ÀÌ ½ÃÀåÀº 2025³âºÎÅÍ 2030³â±îÁö ¿¬Æò±Õ 8.5%ÀÇ ¼ºÀå·üÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÇコÄÉ¾î »ê¾÷ÀÇ ±â¼ú ¹ßÀü°ú ÃÖÁ¾»ç¿ëÀÚ Áõ°¡°¡ ¹Ì±¹ ½ÃÀåÀÇ ¼ºÀåÀ» ÃËÁøÇÏ´Â ÁÖ¿ä ¿äÀÎÀ¸·Î ²ÅÈü´Ï´Ù.
ÀǾàǰ ºÐ¼® ½ÃÇè ¾Æ¿ô¼Ò½ÌÀ» ÅëÇØ ±â¾÷Àº º¸´Ù º¹ÀâÇÑ ¾÷¹«¿Í ¹Ýº¹ÀûÀÎ ¾÷¹«¸¦ ó¸®ÇÒ ¼ö ÀÖÀ¸¸ç, µ¿½Ã¿¡ ÇÙ½É ¿ª·®¿¡ ÁýÁßÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÇ·á±â°üÀº Àü¹® ½Ã¼³ °³¹ß ¹× Á÷¿ø °í¿ëÀ» ÇÇÇÒ ¼ö ÀÖ¾î ºñ¿ëÀ» Àý°¨ÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀǾàǰ ¹× Ä¡·á ¿ë¾×¿¡ Æ÷ÇÔµÈ ¼ººÐÀÇ ½Äº° ¹× ÃøÁ¤Àº ÀǾàǰ ºÐ¼® ½ÃÇè¿¡ Æ÷ÇԵ˴ϴÙ. ¿¬±¸ °³¹ß ÅõÀÚ Áõ°¡¿Í ÀǾàǰ ¼ö¿ä Áõ°¡·Î ÀÎÇØ ½ÃÀåÀº Æò°¡ ±â°£ µ¿¾È È®´ëµÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
ÀǾàǰ ºÐ¼® ½ÃÇè ¾Æ¿ô¼Ò½ÌÀº COVID-19 »çÅ·ΠÀÎÇØ Å« ¿µÇâÀ» ¹Þ°í ÀÖ½À´Ï´Ù. ¿©·¯ Á¦¾àȸ»çÀÇ »ç³» ½ÇÇè½Ç °Ë»ç ´É·ÂÀÌ Ãà¼ÒµÇ°Å³ª Áß´ÜµÇ¸é¼ ÀÇ·á ÀÎÇÁ¶óÀÇ Áß¿äÇÑ ±¸¼º¿ä¼ÒÀÎ ÀǾàǰ ºÐ¼® ¼ºñ½º´Â óÀ½¿¡ ÁߴܵǾú½À´Ï´Ù. Á÷¿øµéÀº Ãʱ⿡´Â ¹ÙÀÌ·¯½º È®»ê ¿ì·Á·Î ÀÎÇÑ ½ÇÇè½Ç ¿ë·® °¨¼Ò, IT ¹®Á¦, °Ë»ç¸¦ À§ÇÑ »ùÇà Àü¼ÛÀÇ ¾î·Á¿ò µî ¿©·¯ °¡Áö ¾î·Á¿ò¿¡ Á÷¸éÇß½À´Ï´Ù. ±×·¯³ª ÀÌ·¯ÇÑ ¾î·Á¿òÀ» ¿ÏÈÇϰųª ¹æÁöÇϱâ À§ÇØ ±³´ë ±Ù¹«, Àη °¨Ãà, ÀçÅà ±Ù¹« µî ´Ù¾çÇÑ Àü·«À» äÅÃÇß½À´Ï´Ù.
´Ù¾çÇÑ ±â¾÷µéÀÌ ´Ù¾çÇÑ Ã·´Ü °Ë»ç ¹× ¼Ö·ç¼ÇÀ» °³¹ßÇÏ¿© COVID-19 »çŸ¦ ¸·±â À§ÇÑ Á¤ºÎÀÇ ³ë·ÂÀ» Áö¿øÇß½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¾÷µéÀº COVID-19°¡ ºñÁî´Ï½º¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» ÁÙÀÏ ¼ö ÀÖ¾ú½À´Ï´Ù. ¿¹¸¦ µé¾î, À¯·ÎÇɽº ¿¬±¸¼Ò´Â 4,000¸¸ °³ÀÇ COVID-19 °Ë»ç ŰƮ¸¦ ¼º°øÀûÀ¸·Î »ý»êÇß½À´Ï´Ù. ¶ÇÇÑ, ´Ù¾çÇÑ º¯Á¾¿¡ ´ëÇÑ »õ·Î¿î °Ë»ç ŰƮ¸¦ ¸¸µé°í ÀÖÀ¸¸ç, WHO°¡ COVID-19¸¦ ¿ì·ÁÇÒ ¸¸ÇÑ º¯Á¾À¸·Î ºÐ·ùÇßÀ» ¶§ Áï½Ã ¿À¹ÌÅ©·Ð °Ë»ç ŰƮ¸¦ Ãâ½ÃÇß½À´Ï´Ù.
¹Ì±¹ÀÇ ÀǾàǰ ºÐ¼® ½ÃÇè ¾Æ¿ô¼Ò½Ì ½ÃÀå º¸°í¼ ÇÏÀ̶óÀÌÆ®:
- ¹ÙÀÌ¿À Á¦¾à ¾÷°è ±â¾÷µéÀÌ Á¶»ç°³¹ß¿¡ ÀÚ±ÝÀ» ÅõÀÚÇÏ°í ºÐ¼® ½ÃÇè ¾Æ¿ô¼Ò½ÌÀ» ¼±È£ÇÏ´Â °æÇâÀÌ °ÇØÁö¸é¼ ¹ÙÀÌ¿À ºÐ¼® ½ÃÇè ºÎ¹®ÀÌ 2024³â ¸ÅÃâ Á¡À¯À² 52.2%·Î ½ÃÀåÀ» Àå¾ÇÇß½À´Ï´Ù.
- ¹æ¹ý °³¹ß ¹× °ËÁõ ºÐ¾ß¿¡¼´Â ÃßÃâ ¹× Ä§Ã⼺ ¼ºñ½º°¡ 2024³â 23.55%ÀÇ ºÎ¹® Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.
- Á¦¾à ±â¾÷ ºÎ¹®Àº 2024³â 45.61%·Î °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇßÀ¸¸ç, ü¿Ü ¹× »ýü ³» ½ÃÇè¿¡ ´ëÇÑ ±ÔÁ¦ º¯È, ÷´Ü ±â¼ú, ½ÃÇèÀÇ º¹À⼺À» ÁÙÀ̱â À§ÇÑ µ¶Ã¢ÀûÀÎ ¹æ¹ý µîÀÌ Á¦¾à ºÐ¼® ½ÃÇè ¼ºñ½º ¾Æ¿ô¼Ò½ÌÀ» Áõ°¡½ÃŰ´Â ¿äÀÎ Áß ÀϺÎÀÔ´Ï´Ù.
- West Pharmaceutical Services, Inc, SGS SA, Eurofins Scientific, Pace Analytical Services Llc, Intertek Group Plc µîÀÌ ½ÃÀå ¼ºÀå¿¡ ±â¿©ÇÏ´Â ÁÖ¿ä ±â¾÷ÀÔ´Ï´Ù.
- ÃÖÁ¾ ¿ëµµº°·Î´Â ÀÓ»ó½ÃÇè µî·Ï ¹× ½ÃÀå ÁøÀÔ Áõ°¡·Î ÀÎÇØ ¹ÙÀÌ¿ÀÁ¦¾à ±â¾÷ÀÌ ¿¹Ãø ±â°£ µ¿¾È °¡Àå ºü¸¥ ¼ºÀåÀ» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
¸ñÂ÷
Á¦1Àå Á¶»ç ¹æ¹ý°ú ¹üÀ§
Á¦2Àå ÁÖ¿ä ¿ä¾à
Á¦3Àå ¹Ì±¹ÀÇ ÀǾàǰ ºÐ¼® ½ÃÇè ¾Æ¿ô¼Ò½Ì ½ÃÀå º¯¼ö, µ¿Çâ, ¹üÀ§
- ½ÃÀå °èÅë Àü¸Á
- »óºÎ ½ÃÀå Àü¸Á
- °ü·Ã/º¸Á¶ ½ÃÀå Àü¸Á
- ½ÃÀå ¿ªÇÐ
- ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ ºÐ¼®
- ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ ºÐ¼®
- ¹Ì±¹ÀÇ ÀǾàǰ ºÐ¼® ½ÃÇè ¾Æ¿ô¼Ò½Ì ½ÃÀå ºÐ¼® Åø
- ¾÷°è ºÐ¼® - Porter's Five Forces ºÐ¼®
- PESTEL ºÐ¼®
- COVID-19ÀÇ ¿µÇ⠺м®
Á¦4Àå ¹Ì±¹ÀÇ ÀǾàǰ ºÐ¼® ½ÃÇè ¾Æ¿ô¼Ò½Ì ½ÃÀå : ¼ºñ½º ÃßÁ¤¡¤µ¿Ç⠺м®
- ¹Ì±¹ÀÇ ÀǾàǰ ºÐ¼® ½ÃÇè ¾Æ¿ô¼Ò½Ì ½ÃÀå, ¼ºñ½ºº° : ºÎ¹® ´ë½Ãº¸µå
- ¹Ì±¹ÀÇ ÀǾàǰ ºÐ¼® ½ÃÇè ¾Æ¿ô¼Ò½Ì ½ÃÀå, ¼ºñ½ºº° : º¯µ¿ ºÐ¼®
- ¼ºñ½ºº°, 2018-2030³â
- »ýü ºÐ¼® ½ÃÇè
- ¹ÙÀÌ¿À ºÐ¼® °Ë»ç ½ÃÀå, 2018-2030³â
- ÀÓ»ó
- ºñÀÓ»ó
- ¹æ¹ý °³¹ß°ú °ËÁõ
- ±â¹ý °³¹ß ¹× °ËÁõ ½ÃÀå, 2018-2030³â
- ÃßÃâ °¡´É ¹× ħÃâ °¡´É
- ºÒ¼ø¹°¹ý
- ±â¼ú ÄÁ¼³ÆÃ
- ±âŸ ¹æ¹ý °ËÁõ ¼ºñ½º
- ¾ÈÁ¤¼º Å×½ºÆ®
- ¾ÈÁ¤¼º ½ÃÇè ½ÃÀå, 2018-2030³â
- ¾à¹° ¼ººÐ
- ¾ÈÁ¤¼º Áö½Ã¹ý °ËÁõ
- °¡¼Ó ¾ÈÁ¤¼º ½ÃÇè
- ±¤¾ÈÁ¤¼º ½ÃÇè
- ±âŸ ¾ÈÁ¤¼º ½ÃÇè ¹æ¹ý
- ±âŸ Å×½ºÆ® ¼ºñ½º
- ±âŸ Å×½ºÆ® ¼ºñ½º ½ÃÀå, 2018-2030³â
Á¦5Àå ¹Ì±¹ÀÇ ÀǾàǰ ºÐ¼® ½ÃÇè ¾Æ¿ô¼Ò½Ì ½ÃÀå : ÃÖÁ¾ ¿ëµµ ÃßÁ¤¡¤µ¿Ç⠺м®
- ¹Ì±¹ÀÇ ÀǾàǰ ºÐ¼® ½ÃÇè ¾Æ¿ô¼Ò½Ì ½ÃÀå, ÃÖÁ¾ ¿ëµµº° : ºÎ¹® ´ë½Ãº¸µå
- ¹Ì±¹ÀÇ ÀǾàǰ ºÐ¼® ½ÃÇè ¾Æ¿ô¼Ò½Ì ½ÃÀå, ÃÖÁ¾ ¿ëµµº° : º¯µ¿ ºÐ¼®
- ÃÖÁ¾ ¿ëµµº°, 2018-2030³â
- Á¦¾àȸ»ç
- ¹ÙÀÌ¿ÀÀǾàǰ ±â¾÷
- ÀÓ»ó½ÃÇè¼öʱâ°ü
Á¦6Àå °æÀï »óȲ
- ½ÃÀå ÁøÃâ ±â¾÷ ºÐ·ù
- À̳뺣ÀÌÅÍ
- ½ÃÀå ¸®´õ
- ½ÅÈï ±â¾÷
- ±â¾÷ ½ÃÀå Á¡À¯À² ºÐ¼®, 2024³â
- ±â¾÷ °³¿ä
- West Pharmaceutical Services, Inc.
- SGS SA
- Eurofins Scientific
- Pace Analytical Services Llc
- Intertek Group PLC
- Pharmaceutical Product Development, LLC.
- Wuxi Apptec, Inc.
- Boston Analytical
- Charles River Laboratories International, Inc.
ksm 24.11.20
U.S. Pharmaceutical Analytical Testing Outsourcing Market Growth & Trends:
The U.S. pharmaceutical analytical testing outsourcing market size is expected to reach USD 5.09 billion by 2030, according to a new report by Grand View Research, Inc. The market is anticipated to expand at a CAGR of 8.5% from 2025 to 2030. Technological advancements in the healthcare industry and an increase in end-users are the key factors driving the growth of the U.S. market.
Analytical testing services outsourcing allows companies to handle more complex or repetitive tasks while also assisting companies in concentrating on their core competencies. Enabling medical organizations to avoid developing specialized facilities and hiring staff, results in cost savings. The identification and measurement of ingredients in drugs or therapeutic solutions are included in pharmaceutical analytical testing. The market is anticipated to expand during the assessment period as a result of rising R&D investments and rising drug demand.
The outsourcing of pharmaceutical analytical testing has been significantly impacted by the COVID-19 pandemic. Due to various pharmaceutical companies' internal lab testing capacities being reduced or shut down, the pharmaceutical analytical services-an important component of the healthcare infrastructure-were initially disrupted. The workers initially faced several difficulties, including reduced lab capacity because of concerns about spreading the virus, IT issues, and difficulties sending samples for testing. However, various strategies, including rotating shifts, reducing manpower, and working from home, have been adopted by companies to mitigate or prevent these difficulties.
Various companies supported the government's efforts to stop the COVID-19 pandemic by producing various cutting-edge tests and solutions. These businesses were able to reduce the effects of COVID-19 on their operations. For example, 40 million COVID-19 tests were successfully manufactured by Eurofins laboratories. Additionally, new test kits are being created for various variants. When WHO classified it as a variant of concern, they released an omicron test kit the same day.
U.S. Pharmaceutical Analytical Testing Outsourcing Market Report Highlights:
- The bioanalytical testing segment dominated the market with a revenue share of 52.2% in 2024 due to players in the biopharmaceutical industry spending money on R&D and a growing preference for outsourcing analytical testing.
- By method development and validation segment, the extractable and leachable services held 23.55% segment share in 2024.
- The pharmaceutical companies segment accounted for the largest share of 45.61% in 2024. Changing regulations for in vitro and in vivo tests, sophisticated technologies, and creative methods to reduce test complexity are some of the factors that are causing more pharmaceutical analytical testing services to be outsourced.
- West Pharmaceutical Services, Inc., SGS SA, Eurofins Scientific, Pace Analytical Services Llc, and Intertek Group Plc are some of the major key players contributing to the growth of the market.
- Based on end-user, biopharmaceutical companies are anticipated to register the fastest growth over the forecast period due to an increase in the number of clinical trial registrations and market entrants.
Table of Contents
Chapter 1. Research Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.2. Segment Definitions
- 1.2.1. Services
- 1.2.2. End Use
- 1.3. Regional Scope
- 1.4. Estimates And Forecast Timeline
- 1.5. Research Methodology
- 1.6. Information Procurement
- 1.6.1. Purchased Database
- 1.6.2. GVR's Internal Database
- 1.6.3. Secondary Sources
- 1.6.4. Primary Research
- 1.7. Information Or Data Analysis
- 1.7.1. Data Analysis Models
- 1.8. Market Formulation & Validation
- 1.9. Model Details
- 1.9.1. Commodity Flow Analysis
- 1.9.2. Parent Market Analysis
- 1.10. Objectives
Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Snapshot
- 2.3. Competitive Landscape Snapshot
Chapter 3. U.S. Pharmaceutical Analytical Testing Outsourcing Market Variables, Trends & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent Market Outlook
- 3.1.2. Related/Ancillary Market Outlook
- 3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
- 3.2.1.1. Increasing innovation in testing services
- 3.2.1.2. Growing regulation, safety & quality requirements
- 3.2.1.3. Competitive Pricing Strategies
- 3.2.2. Market Restraint Analysis
- 3.2.2.1. Data insecurity
- 3.2.2.2. Third-party performance
- 3.3. U.S. Pharmaceutical Analytical Testing Outsourcing Market Analysis Tools
- 3.3.1. Industry Analysis - Porter's
- 3.3.2. PESTEL Analysis
- 3.3.3. COVID-19 Impact Analysis
Chapter 4. U.S. Pharmaceutical Analytical Testing Outsourcing Market: Services Estimates & Trend Analysis
- 4.1. U.S. Pharmaceutical Analytical Testing Outsourcing Market, By Services: Segment Dashboard
- 4.2. U.S. Pharmaceutical Analytical Testing Outsourcing Market, By Services: Movement Analysis
- 4.3. U.S. Pharmaceutical Analytical Testing Outsourcing Market Estimates & Forecasts, By Services, 2018 - 2030
- 4.4. Bioanalytical Testing
- 4.4.1. Bioanalytical Testing Market, 2018 to 2030 (USD Million)
- 4.4.2. Clinical
- 4.4.2.1. Clinical Market, 2018 to 2030 (USD Million)
- 4.4.3. Non- Clinical
- 4.4.3.1. Non- Clinical Market, 2018 to 2030 (USD Million)
- 4.5. Method Development and Validation
- 4.5.1. Method Development and Validation Market, 2018 to 2030 (USD Million)
- 4.5.2. Extractable and Leachable
- 4.5.2.1. Extractable and Leachable Market, 2018 to 2030 (USD Million)
- 4.5.3. Impurity Method
- 4.5.3.1. Impurity Method Market, 2018 to 2030 (USD Million)
- 4.5.4. Technical Consulting
- 4.5.4.1. Technical Consulting Market, 2018 to 2030 (USD Million)
- 4.5.5. Other Method Validation Services
- 4.5.5.1. Other Method Validation Services Market, 2018 to 2030 (USD Million)
- 4.6. Stability Testing
- 4.6.1. Stability Testing Market, 2018 to 2030 (USD Million)
- 4.6.2. Drug Substance
- 4.6.2.1. Drug Substance Market, 2018 to 2030 (USD Million)
- 4.6.3. Stability Indicating Method Validation
- 4.6.3.1. Stability Indicating Method Validation Market, 2018 to 2030 (USD Million)
- 4.6.4. Accelerated Stability Testing
- 4.6.4.1. Accelerated Stability Testing Market, 2018 to 2030 (USD Million)
- 4.6.5. Photostability Testing
- 4.6.5.1. Photostability Testing Market, 2018 to 2030 (USD Million)
- 4.6.6. Other Stability Testing Methods
- 4.6.6.1. Other Stability Testing Methods Market, 2018 to 2030 (USD Million)
- 4.7. Other Testing Services
- 4.7.1. Other Testing Services Market, 2018 to 2030 (USD Million)
Chapter 5. U.S. Pharmaceutical Analytical Testing Outsourcing Market: End Use Estimates & Trend Analysis
- 5.1. U.S. Pharmaceutical Analytical Testing Outsourcing Market, By End Use: Segment Dashboard
- 5.2. U.S. Pharmaceutical Analytical Testing Outsourcing Market, By End Use: Movement Analysis
- 5.3. U.S. Pharmaceutical Analytical Testing Outsourcing Market Estimates & Forecasts, By End Use, 2018 - 2030
- 5.4. Pharmaceutical Companies
- 5.4.1. Pharmaceutical Companies Market, 2018 to 2030 (USD Million)
- 5.5. Biopharmaceutical Companies
- 5.5.1. Biopharmaceutical Companies Market, 2018 to 2030 (USD Million)
- 5.6. Contract Research Organizations
- 5.6.1. Contract Research Organizations Market, 2018 to 2030 (USD Million)
Chapter 6. Competitive Landscape
- 6.1. Market Participant Categorization
- 6.1.1. Innovators
- 6.1.2. Market Leaders
- 6.1.3. Emerging Players
- 6.1.4. Company Market Share Analysis, 2024
- 6.2. Company Profiles
- 6.2.1. West Pharmaceutical Services, Inc.
- 6.2.1.1. Company Overview
- 6.2.1.2. Financial Performance
- 6.2.1.3. Service Benchmarking
- 6.2.1.4. Strategic Initiatives
- 6.2.2. SGS SA
- 6.2.2.1. Company Overview
- 6.2.2.2. Financial Performance
- 6.2.2.3. Service Benchmarking
- 6.2.2.4. Strategic Initiatives
- 6.2.3. Eurofins Scientific
- 6.2.3.1. Company Overview
- 6.2.3.2. Financial Performance
- 6.2.3.3. Service Benchmarking
- 6.2.3.4. Strategic Initiatives
- 6.2.4. Pace Analytical Services Llc
- 6.2.4.1. Company Overview
- 6.2.4.2. Financial Performance
- 6.2.4.3. Service Benchmarking
- 6.2.4.4. Strategic Initiatives
- 6.2.5. Intertek Group PLC
- 6.2.5.1. Company Overview
- 6.2.5.2. Financial Performance
- 6.2.5.3. Service Benchmarking
- 6.2.5.4. Strategic Initiatives
- 6.2.6. Pharmaceutical Product Development, LLC.
- 6.2.6.1. Company Overview
- 6.2.6.2. Financial Performance
- 6.2.6.3. Service Benchmarking
- 6.2.6.4. Strategic Initiatives
- 6.2.7. Wuxi Apptec, Inc.
- 6.2.7.1. Company Overview
- 6.2.7.2. Financial Performance
- 6.2.7.3. Service Benchmarking
- 6.2.7.4. Strategic Initiatives
- 6.2.8. Boston Analytical
- 6.2.8.1. Company Overview
- 6.2.8.2. Financial Performance
- 6.2.8.3. Service Benchmarking
- 6.2.8.4. Strategic Initiatives
- 6.2.9. Charles River Laboratories International, Inc.
- 6.2.9.1. Company Overview
- 6.2.9.2. Financial Performance
- 6.2.9.3. Service Benchmarking
- 6.2.9.4. Strategic Initiatives